Get the Stockscreener App
1.96
5.77%
-0.12
Compugen Ltd stock is traded at $1.96, with a volume of 169.43K.
It is down -5.77% in the last 24 hours and down -18.67% over the past month.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
See More
Previous Close:
$2.08
Open:
$2.08
24h Volume:
169.43K
Relative Volume:
0.81
Market Cap:
$185.67M
Revenue:
$72.66M
Net Income/Loss:
$34.86M
P/E Ratio:
5.3552
EPS:
0.366
Net Cash Flow:
$-62.91M
1W Performance:
-7.98%
1M Performance:
-18.67%
6M Performance:
-32.18%
1Y Performance:
+0.51%
1-Day Range:
$1.93
$2.09
1-Week Range:
$1.93
$2.13
52-Week Range:
$1.43
$3.235
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
1.96 | 185.67M | 72.66M | 34.86M | -62.91M | 0.366 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Initiated | Lake Street | Buy |
| Jan-07-26 | Initiated | H.C. Wainwright | Buy |
| Jan-13-25 | Initiated | Oppenheimer | Outperform |
| Aug-05-22 | Downgrade | Jefferies | Buy → Hold |
| May-26-20 | Resumed | JMP Securities | Mkt Outperform |
| May-13-20 | Initiated | Stifel | Buy |
| May-07-20 | Initiated | SVB Leerink | Outperform |
| Apr-22-20 | Initiated | ROTH Capital | Buy |
| Mar-24-20 | Initiated | SunTrust | Buy |
| Jan-16-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-29-18 | Initiated | Oppenheimer | Outperform |
| Feb-01-16 | Resumed | Oppenheimer | Outperform |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Apr-23-15 | Resumed | Jefferies | Buy |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Feb-07-14 | Initiated | MLV & Co | Buy |
| Dec-28-09 | Reiterated | Cantor Fitzgerald | Buy |
| Jul-29-09 | Initiated | Cantor Fitzgerald | Buy |
View All
Compugen Ltd Stock (CGEN) Latest News
Compugen Price Target Maintained With a $4.00/Share by HC Wainwright & Co. - Moomoo
CGEN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $4.00 - GuruFocus
Stifel reiterates Compugen stock rating on ovarian trial update - Investing.com
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference - Yahoo Finance
An online conference on AI drug discovery will include Compugen. - Stock Titan
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets - Yahoo Finance
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets - TradingView
Compugen Ltd. KOL Event (Virtual) Transcript - GuruFocus
Compugen Ltd. (CGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Compugen to host virtual event on COM701 ovaria... - Pluang
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026 - Yahoo Finance
A Harvard cancer expert will discuss an ovarian cancer drug. Compugen's event is Oct. 5. - Stock Titan
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - Eastern Progress
Compugen Shareholders Approve All Proposals at 2026 Annual Meeting - The Globe and Mail
Compugen Shareholders Approve All Proposals at 2026 Annual Meeting - TipRanks
All 2026 AGM proposals pass at Compugen (CGEN) - Stock Titan
Israel National Biotech Innovation Center Launches With Anat Cohen-Dayag as CEO of INBI Core - citybiz
Compugen to present at H.C. Wainwright Investme... - Pluang
A cancer treatment company will speak live Sept. 14. Compugen’s talk will be webcast. - Stock Titan
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy - Yahoo Finance
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates - Eastern Progress
Are Medical Stocks Lagging Compugen (CGEN) This Year? - Yahoo Finance
Compugen (CGEN) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Price Reaction: Shares Finish 1.28% Up on the DayCost Structure Review - dars.gov.et
Compugen (CGEN) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Price Reaction: Shares Finish 1.28% Up on the DayQuarterly Financial Update - dars.gov.et
Compugen (CGEN) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Price Reaction: Shares Finish 1.28% Up on the DayEarnings Surprise Stocks - vinanet.vn
Compugen (CGEN) Dips 2.49% to $2.35, Pressure Mounts Toward Support at $2.23Price Target - vinanet.vn
Compugen (CGEN) Dips 2.49% to $2.35, Pressure Mounts Toward Support at $2.23NAAIM Leverage - dars.gov.et
Analysts Have Just Cut Their Compugen Ltd. (NASDAQ:CGEN) Revenue Estimates By 14% - simplywall.st
CGEN Q2 2026 Earnings: Loss Narrower Than Expected as EPS Surprises PositivelyMargin Expansion Trends - vinanet.vn
CGEN Q2 2026 Earnings: Loss Narrower Than Expected as EPS Surprises PositivelyMargin Expansion Trends - vinanet.vn
Compugen Ltd. (CGEN) Slides 3.6% as Biotech Stock Approaches Key $2.29 SupportBuy Signal Reports - vinanet.vn
Compugen Ltd. (CGEN) Slides 3.6% as Biotech Stock Approaches Key $2.29 SupportRelative Volume - dars.gov.et
Compugen (NASDAQ:CGEN) Share Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Compugen (CGEN) Slips 1.8% to $2.46 as Shares Hover Near Key SupportSingle Stock ETF - Vinanet
Compugen (CGEN) Slips 1.8% to $2.46 as Shares Hover Near Key SupportBPI Bull Confirmed - dars.gov.et
Compugen (CGEN) Gains 4.17% to $2.50 as Immuno-Oncology Stock Shows ResilienceRVOL Breakout - dars.gov.et
Compugen (CGEN) Q2 2026 Earnings Call Transcript - AOL.com
Compugen (CGEN) Q2 2026 Earnings Call Transcript - The Globe and Mail
Compugen (CGEN) Slips 2.9% to $2.34 as Shares Approach Key Support at $2.22RVOL Spike - careplusvn.com
Compugen Ltd. (CGEN) stock price, news, quote and history - Yahoo Finance Singapore
Compugen Ltd (CGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Compugen Ltd (CGEN) Stock News Today - TradingKey
Compugen Ltd. (CGEN) Rises 2.17% to $2.35: Biotech Stock Holds Key Support as Resistance at $2.47 LoomsMFI Overbought - vinanet.vn
Compugen: Better Runway Ahead Of MAIA - Seeking Alpha
FY2026 EPS Estimates for Compugen Raised by HC Wainwright - MarketBeat
Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ... By GuruFocus - Investing.com Canada
Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancin - GuruFocus
Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ... - Yahoo Finance
Compugen Ltd Stock (CGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Compugen Ltd Stock (CGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Levine Zurit | SVP, Business Development |
Jul 09 '26 |
Sale |
2.50 |
1,875 |
4,688 |
29,375 |
| Levine Zurit | SVP, Business Development |
Apr 24 '26 |
Sale |
3.20 |
2,000 |
6,400 |
29,375 |
| Ophir Eran | President and CEO |
Apr 24 '26 |
Option Exercise |
0.83 |
5,000 |
4,146 |
16,375 |
| Ophir Eran | President and CEO |
Apr 24 '26 |
Sale |
3.20 |
5,000 |
16,000 |
11,375 |
| Ophir Eran | Officer |
Apr 24 '26 |
Proposed Sale |
2.92 |
5,000 |
14,600 |
0 |
| Levine Zurit | Officer |
Apr 24 '26 |
Proposed Sale |
2.92 |
4,000 |
11,680 |
0 |
| Levine Zurit | SVP, Business Development |
Apr 24 '26 |
Option Exercise |
1.15 |
2,000 |
2,300 |
31,375 |
| Ophir Eran | President and CEO |
Apr 14 '26 |
Option Exercise |
0.83 |
5,000 |
4,146 |
16,375 |
| Ophir Eran | President and CEO |
Apr 14 '26 |
Sale |
2.90 |
5,000 |
14,521 |
11,375 |
| Levine Zurit | SVP, Business Development |
Apr 14 '26 |
Option Exercise |
1.15 |
2,000 |
2,300 |
31,375 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):